Mooren's ulcer: Difference between revisions
←Removed redirect to Corneal ulcer#Superficial and deep corneal ulcers Tags: Removed redirect Visual edit |
No edit summary |
||
| Line 50: | Line 50: | ||
=== Surgical treatment === |
=== Surgical treatment === |
||
If patients do not respond to medication, surgical intervention must be performed. Conjunctival excision has been shown to be an effective method. The principle of this surgery is based on the removal of unhealthy limbal conjunctiva adjacent to the ulcer. |
If patients do not respond to medication, surgical intervention must be performed. Conjunctival excision has been shown to be an effective method. The principle of this surgery is based on the removal of unhealthy limbal conjunctiva adjacent to the ulcer. slow down the disease progression due to eliminating the local source of inflammatory cells, mediators and enzymes which cause the tissue damage.<ref>{{Cite journal |last=Kalogeropoulos |first=Christos D. |last2=Malamou–Mitsi |first2=Vassiliki D. |last3=Aspiotis |first3=Miltiadis B. |last4=Psilas |first4=Konstantinos G. |date=2004-01-01 |title=Bilateral Mooren's Ulcer in Six Patients: Diagnosis, Surgery and Histopathology |url=https://doi.org/10.1023/B:INTE.0000018510.06715.c9 |journal=International Ophthalmology |language=en |volume=25 |issue=1 |pages=1–8 |doi=10.1023/B:INTE.0000018510.06715.c9 |issn=1573-2630}}</ref> |
||
Other surgical interventions such as lamellar keratectomy, keratoepithelioplasty and corneal transplantation have been reported as treatment options for Mooren’s ulcer. |
Other surgical interventions such as lamellar keratectomy, keratoepithelioplasty and corneal transplantation have been reported as treatment options for Mooren’s ulcer. |
||
Revision as of 00:48, 13 September 2022
Mooren's ulcer is a rare idiopathic ocular disorder that may lead to blindness due to progressive destruction of the peripheral cornea. Although the etiology of Mooren's ulcer is poorly understood, recent evidence suggests that the pathogenesis of this disease appears to be the result of an autoimmune process directed against molecules expressed in the corneal stroma. [1]
Mooren's ulcer is also defined as a special and the most common type of peripheral ulcerative keratitis (PUK).
Clinical characteristics
Symptoms of Mooren's ulcer can include:
- Pain in the affected eye(s)
- Redness of the affected eye(s)
- Progressive ulceration of the cornea
- Blurred vision
- Photophobia
- Tearing
Some epidemiological studies have noted that men tend to be affected more than women.[2][3]
Risk factors
Several risk factors affecting the development of Mooren's ulcer have been suggested.
Corneal trauma
Previous ocular trauma or infection can cause disruption of the corneal integrity resulting in the expression of tissue-specific antigens that are normally hidden from the immune system. It may lead to an increased risk of a sensitization to corneal antigens and an autoimmune reaction against antigens expressed in corneal tissues.
HLA association
Like most autoimmune diseases, Mooren's ulcer is thought to be associated with specific HLA haplotypes. In some studies, HLA-DR17 and HLA-DQ2 have been found in increased frequencies in affected patients compared to healthy controls. These results propose a possible association between HLA and Mooren's ulcer.[4]
Pathology
The precise pathophysiological mechanism of Mooren's ulcer remains unclear, but most data suggest that both cell-mediated immunity and humoral immunity are involved in the pathogenesis of the disease.
Immunohistochemical studies in patients suffered from Mooren's ulcer showed massive infiltration of multiple types of inflammatory cells in the conjunctival tissue.
The cell types in the inflammatory lesion includes CD4+ and CD8+ T-lymphocytes, B-lymphocytes, macrophages, a small amount of neutrophils was also observed in the conjunctiva from patients with Mooren's ulcer. [5][6][7]
In addition, circulating IgG antibodies with specificity for corneal and conjunctival antigens have been isolated from patients with Mooren’s ulcer.[8] Gottsch and colleagues have suggested that calgranulin C, a protein expressed in the corneal stroma, may be a possible main target for autoimmune response causing Mooren’s ulcer.[9]
Also, significantly increased expression levels of adhesion and co-stimulatory molecules have been found in ocular tissues affected by Mooren's ulcer compared to healthy eyes. Upregulation of adhesion molecules allows leukocyte migration into inflamed tissues. Co-stimulatory molecules may contribute to sustained local immune activation. Therefore, blockage of these molecules suppose to be a protentional therapeutic strategy for suppressing the inflammatory progression.[7]
Elevated levels of proteases and collagenases which damage the corneal stroma have also been found in affected conjunctival tissues.[10]
Diagnosis
In view of rarity and limited knowledge of the etiology of Mooren’s ulcer, the diagnosis of the disease is complicated.
The absence of any systematic disorders which can lead to peripheral corneal ulceration supports the diagnosis of Mooren’s ulcer. To diagnose Mooren’s ulcer, it is necessary to rule out other forms of non-infectious peripheral ulcerative keratitis.[11]
Treatment
Medical treatment
Topical corticosteroids are usually used as first line of therapy. Severe cases require administration of systemic immunosuppressive agents. The more commonly used drugs are cyclosporine A, methotrexate and cyclophosphamide.
Several case reports showed that biological agents, such as anti-tumor necrosis factor alpha (anti-TNF) or monoclonal antibodies against CD20, also can be used as an effective treatment of progressive Mooren’s ulceration.[12][13]
Surgical treatment
If patients do not respond to medication, surgical intervention must be performed. Conjunctival excision has been shown to be an effective method. The principle of this surgery is based on the removal of unhealthy limbal conjunctiva adjacent to the ulcer. slow down the disease progression due to eliminating the local source of inflammatory cells, mediators and enzymes which cause the tissue damage.[14]
Other surgical interventions such as lamellar keratectomy, keratoepithelioplasty and corneal transplantation have been reported as treatment options for Mooren’s ulcer.
References
- ^ Zelefsky, Joseph R; Srinivasan, Muthiah; Cunningham, Emmett T (2011-08). "Mooren's ulcer". Expert Review of Ophthalmology. 6 (4): 461–467. doi:10.1586/eop.11.46. ISSN 1746-9899.
{{cite journal}}: Check date values in:|date=(help) - ^ Dong, Yanling; Zhang, Yangyang; Xie, Lixin; Ren, Jianmei (2017-02). "Risk Factors, Clinical Features, and Treatment Outcomes of Recurrent Mooren Ulcers in China". Cornea. 36 (2): 202–209. doi:10.1097/ico.0000000000001084. ISSN 0277-3740.
{{cite journal}}: Check date values in:|date=(help) - ^ Srinivasan, M.; Zegans, M. E; Zelefsky, J. R; Kundu, A.; Lietman, T.; Whitcher, J. P; Cunningham, E. T (2006-10-11). "Clinical characteristics of Mooren's ulcer in South India". British Journal of Ophthalmology. 91 (5): 570–575. doi:10.1136/bjo.2006.105452. ISSN 0007-1161.
- ^ Taylor, Craig J.; Smith, Sheila I.; Morgan, Catherine H.; Stephenson, Susan F.; Key, Tim; Srinivasan, M.; Cunningham, Emmett; Watson, Peter G. (2000-01-01). "HLA and Mooren's ulceration". British Journal of Ophthalmology. 84 (1): 72–75. doi:10.1136/bjo.84.1.72. ISSN 0007-1161. PMID 10611103.
- ^ Lee, Hyun Ju; Kim, Mee Kum; Wee, Won Ryang; Oh, Joo Youn (2015-09). "Interplay of Immune Cells in Mooren Ulcer". Cornea. 34 (9): 1164–1167. doi:10.1097/ICO.0000000000000471. ISSN 0277-3740.
{{cite journal}}: Check date values in:|date=(help) - ^ Shinomiya, Katsuhiko; Ueta, Mayumi; Sotozono, Chie; Inatomi, Tsutomu; Yokoi, Norihiko; Koizumi, Noriko; Kinoshita, Shigeru (2013-03-01). "Immunohistochemical analysis of inflammatory limbal conjunctiva adjacent to Mooren's ulcer". British Journal of Ophthalmology. 97 (3): 362–366. doi:10.1136/bjophthalmol-2012-302631. ISSN 0007-1161. PMID 23292924.
- ^ a b Kafkala, Chrysanthi; Choi, John; Zafirakis, Panayotis; Baltatzis, Stefanos; Livir-Rallatos, Charalampos; Rojas, Blanca; Foster, C. Stephen (2006-07). "Mooren Ulcer: An Immunopathologic Study". Cornea. 25 (6): 667–673. doi:10.1097/01.ico.0000214216.75496.7e. ISSN 0277-3740.
{{cite journal}}: Check date values in:|date=(help) - ^ Gottsch, John D.; Liu, Sammy H.; Stark, Walter J. (1992-04). "Mooren's Ulcer and Evidence of Stromal Graft Rejection After Penetrating Keratoplasty". American Journal of Ophthalmology. 113 (4): 412–417. doi:10.1016/s0002-9394(14)76164-1. ISSN 0002-9394.
{{cite journal}}: Check date values in:|date=(help) - ^ Gottsch, J. D.; Li, Q.; Ashraf, F.; O'Brien, T. P.; Stark, W. J.; Liu, S. H. (1999-04-01). "Cytokine-Induced Calgranulin C Expression in Keratocytes". Clinical Immunology. 91 (1): 34–40. doi:10.1006/clim.1998.4681. ISSN 1521-6616.
- ^ Brown, S. I. (1975-11-01). "Mooren's ulcer. Histopathology and proteolytic enzymes of adjacent conjunctiva". British Journal of Ophthalmology. 59 (11): 670–674. doi:10.1136/bjo.59.11.670. ISSN 0007-1161.
- ^ Srinivasan, M.; Zegans, M. E; Zelefsky, J. R; Kundu, A.; Lietman, T.; Whitcher, J. P; Cunningham, E. T (2006-10-11). "Clinical characteristics of Mooren's ulcer in South India". British Journal of Ophthalmology. 91 (5): 570–575. doi:10.1136/bjo.2006.105452. ISSN 0007-1161.
- ^ Xia, Annie; Dietrich-Ntoukas, Tina; Pleyer, Uwe (2022-01-20). "Effect of Anti-TNF Treatment on Mooren's Ulcer: A Case Series and Review of the Literature". Ocular Immunology and Inflammation. 0 (0): 1–7. doi:10.1080/09273948.2021.2023581. ISSN 0927-3948. PMID 35050832.
- ^ Guindolet, Damien; Reynaud, Clotilde; Clavel, Gaelle; Belangé, Georges; Benmahmed, Maycene; Doan, Serge; Hayem, Gilles; Cochereau, Isabelle; Gabison, Eric E (2016-07-22). "Management of severe and refractory Mooren's ulcers with rituximab". British Journal of Ophthalmology. 101 (4): 418–422. doi:10.1136/bjophthalmol-2016-308838. ISSN 0007-1161.
- ^ Kalogeropoulos, Christos D.; Malamou–Mitsi, Vassiliki D.; Aspiotis, Miltiadis B.; Psilas, Konstantinos G. (2004-01-01). "Bilateral Mooren's Ulcer in Six Patients: Diagnosis, Surgery and Histopathology". International Ophthalmology. 25 (1): 1–8. doi:10.1023/B:INTE.0000018510.06715.c9. ISSN 1573-2630.